Dolutegravir / rilpivirine | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Dolutegravir / Rilpivirine
Health Canada Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Dolutegravir / rilpivirine

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

51 API Suppliers, 25 USDMF, 9 EU WC, 2 KDMF, 13 NDC API, 33 Listed Suppliers, $ API Reference Price

51 API Suppliers
25 USDMF
9 EU WC
2 KDMF
13 NDC API
33 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

26 Drugs in Development

26 Drugs in Development

INTERMEDIATES

41 Intermediate Suppliers

41 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

87 FDF Dossiers, 28 FDA Orange Book, 10 Europe, 7 Canada, 1 Australia, 39 South Africa, 2 Listed Dossiers

87 FDF Dossiers
28 FDA Orange Book
10 Europe
7 Canada
1 Australia
39 South Africa
2 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 50MG BASE, TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG

TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 50MG BASE
TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Rochem International Inc, 15 SPI Pharma, 2 Seqens, 3 DKSH, 5 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 6 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 Pramukh Pharmachem, 3 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 20 BASF, 5 Corel Pharma Chem, 5 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 3 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 22 Kerry, 12 Microlex e.U, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 2 Novo Excipients, 3 Pharmatrans-Sanaq, 5 Pluviaendo, 4 Prachin Chemical, 13 Roquette, 2 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 1 Ulanqab Kema New Material, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

64 Fillers, Diluents & Binders, 24 Direct Compression, 22 Coating Systems & Additives, 22 Disintegrants & Superdisintegrants, 19 Granulation, 18 Lubricants & Glidants, 17 Thickeners and Stabilizers, 16 Solubilizers, 15 Controlled & Modified Release, 14 Co-Processed Excipients, 14 Chewable & Orodispersible Aids, 12 Parenteral, 12 Taste Masking, 10 Topical, 5 Film Formers & Plasticizers, 3 Coloring Agents, 2 API Stability Enhancers, 2 Surfactant & Foaming Agents, 2 Rheology Modifiers, 2 Emulsifying Agents

64 Fillers, Diluents & Binders
24 Direct Compression
22 Coating Systems & Additives
22 Disintegrants & Superdisintegrants
19 Granulation
18 Lubricants & Glidants
17 Thickeners and Stabilizers
16 Solubilizers
15 Controlled & Modified Release
14 Co-Processed Excipients
14 Chewable & Orodispersible Aids
12 Parenteral
12 Taste Masking
10 Topical
5 Film Formers & Plasticizers
3 Coloring Agents
2 API Stability Enhancers
2 Surfactant & Foaming Agents
2 Rheology Modifiers
2 Emulsifying Agents

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 127 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
1 STOCK RECAP #PipelineProspector
127 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 12 Finished Drug Prices, 32 Annual Reports

3 US Medicaid Prescriptions
12 Finished Drug Prices
32 Annual Reports

MARKET PLACE

9 APIs, 8 FDF Dossiers

9 APIs
8 FDF Dossiers

PATENTS & EXCLUSIVITIES

36 US Patents, 5 US Exclusivities, 1 Health Canada Patents

36 US Patents
5 US Exclusivities
1 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 Others

1 Others

$ API Ref.Price (USD/KG) : 431 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

1 All

01 1GlaxoSmithKline Inc.

filter Patent Reset all filters

1 All

01 12606282

filter Product Reset all filters

1 All

01 1DOLUTEGRAVIR SODIUM

filter Dosage Reset all filters

1 All

01 1TABLET

filter Exp Date Reset all filters

1 All

01 12026-04-28

Product Main Page

01

GlaxoSmithKline Inc.

Dolutegravir Sodium

BioAsia

Not Confirmed

GlaxoSmithKline Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-04-28

Date Granted : 2016-04-26

Dolutegravir Sodium

Brand Name : TIVICAY

Patent Number : 2606282

Filing Date : 2006-04-28

Strength per Unit : 50 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2026-04-28

Date Granted : 2016-04-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!